Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Molecular Features of Hormone-Refractory Prostate Cancer Cells by Genome-wide Gene-expression Profiles

ABSTRACT: To characterize the molecular features of clinical (Hormone-Refractory Prostate Cancers) HRPCs, we generated the precise gene-expression profiles of 25 clinical HRPCs and 10 hormone-sensitive prostate cancers (HSPCs) by genome-wide cDNA microarrays combining with laser microbeam microdisection. Keywords: disease status analysis

ORGANISM(S): Homo sapiens

PROVIDER: GSE6811 | GEO | 2007/06/01

SECONDARY ACCESSION(S): PRJNA99185

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcription profiling of hormone sensitive and hormone refractory human prostate cancer xenografts grown in mice

Project description:Seven pairs of hormone sensitive and hormone refractory prostate cancer xenografts

2007-12-12 | E-GEOD-847 | biostudies-arrayexpress

Effects of WCE herbal extract on hormone-refractory PC-3 tumors

Project description:Purpose: Androgen-deprivation therapy is the standard treatment for prostate cancer but fails in hormone-refractory prostate cancer. The anti-inflammatory plant Wedelia chinensis is rich in luteolin, apigenin, and wedelolactone that act synergistically to suppress androgen receptor activity in prostate cancer. Here, we evaluated the systemic antitumor effects of a standardized and effect-optimized Wedelia chinensis herbal extract (WCE) on hormone-refractory prostate cancer. Methods: Hormone-refractory PC-3 orthotopic tumor mouse models were orally administered with WCE. The tumor transcriptomes were studied using RNA sequencing and Ingenuity Pathway Analysis to identify the molecular mechanisms. Results: WCE significantly attenuated tumor growth and metastasis in orthotopic PC-3 xenografts. Transcriptomic analysis of genome-wide gene expression in the tumors revealed that WCE suppressed the expression of HIF1α, IKKα/β phosphorylation, and the downstream cytokines/chemokines. Conclusions: A standardized preparation of Wedelia chinensis improved prostate cancer therapy through repressing NFκB-mediated cytokine expression in tumor cells and modulating the inflammatory tumor microenvironment. These data suggest that WCE functions through immunomodulation and has potential application as an adjuvant agent for the treatment of castration-resistant prostate cancer.

2017-12-01 | GSE99820 | GEO

Refractory Cancers (RC) HOPE-CARE

Project description:Refractory Cancers (RC) HOPE-CARE

| PRJNA671240 | ENA

Androgen Receptor is a Backdoor Inhibitor of Wildtype and Mutant Estrogen Receptors in Refractory Hormone Receptor-Positive Breast Cancers

Project description:Androgen Receptor is a Backdoor Inhibitor of Wildtype and Mutant Estrogen Receptors in Refractory Hormone Receptor-Positive Breast Cancers

| PRJNA526053 | ENA

HS to HR progression

Project description:Seven pairs of hormone sensitive and hormone refractory prostate cancer xenografts Keywords: parallel sample

2004-01-01 | GSE847 | GEO

Genomic profiling of relapsed and refractory childhood cancers

Project description:Genomic profiling of relapsed and refractory childhood cancers

| PRJNA661354 | ENA

Genomic profiling of relapsed and refractory childhood cancers

Project description:Genomic profiling of relapsed and refractory childhood cancers

| PRJNA661355 | ENA

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

Project description:To evaluate the safety, tolerability, efficacy, and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, clear cell renal cell cancer or hormone refractory prostate cancer

| 2037574 | ecrin-mdr-crc

Transcription profiling of human hormone resistant prostate cancer

Project description:In this study we performed transcriptional profiling of transurethral resections of hormone resistant prostate cancer and compared it with benign prostatic hyperplasia (BPH), untreated localized prostate cancer and hormone sensitive prostate cancer. Experiment Overall Design: Each sample (= Array) is derived from a different patient with the following subsequent disease states: 3x BPH, 7x localized prostate cancer samples, 2 horomone sensitive prostate cancer samples, one locally advanced prostate cancer, 4x hormone resistant prostate cancer early stage and 3x hormone resistant prostate cancer late stage. Experiment Overall Design: Platform was Affymetrix

2008-06-13 | E-GEOD-5377 | biostudies-arrayexpress

Proteomics of EBV-infected lytic and refractory cells

Project description:Most humans are infected with Epstein-Barr virus (EBV), a cancer-causing virus. While EBV generally persists silently in B lymphocytes, periodic lytic (re-)activation of latent virus is central to its life cycle and to most EBV-related diseases. However, a substantial fraction of EBV-infected B cells and tumor cells in a population is refractory to lytic activation. This resistance to lytic activation directly and profoundly impacts viral persistence and effectiveness of oncolytic therapy for EBV+ cancers. To identify the mechanisms that underlie susceptibility to EBV-lytic activation, we used host protein-expression profiling of separated-lytic and -refractory cells.

2016-04-27 | PXD001838 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data